Navigation Links
Laparoscopic Surgeons Develop Fluorescent Light Technique to Improve Pancreatic Cancer Detection
Date:10/24/2011

SAN FRANCISCO, Oct. 24, 2011 /PRNewswire-USNewswire/ -- More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal.  However, surgeons and scientists at the University of California-San Diego (UCSD) are developing a laparoscopic technique that uses fluorescent light to improve pancreatic cancer staging and treatment.  Their findings were presented today at the 2011 Clinical Congress of the American College of Surgeons.

The UCSD researchers compared a standard xenon laparoscope with a laparoscope using a light emitting diode (LED) source.  Surgeons took two antibodies that are commonly expressed by pancreatic cancer and tagged them with a fluorescent marker, thus, making the cancerous tumors "light up" in colors of bright green or red, reported study leaders, Michael Bouvet, MD, FACS, and Robert M. Hoffman, Ph.D., both UCSD professors of surgery.

The surgeons and scientists then administered fluorescent antibodies into six-week old female mice.  The researchers were able to see primary and metastatic tumors more vividly with the LED light, at a sensitivity rate of 96 percent, than with traditional laparoscopy, which had a sensitivity rate of 40 percent.  Moreover, fluorescent laparoscopy rendered fewer false positives than traditional laparoscopy, and the researchers were able to clearly see the surrounding anatomy in the abdominal cavity of the mice.  Fluorescent laparoscopy was also sensitive enough to illuminate metastatic lesions smaller than one millimeter, which are not visible with a standard laparoscope.

"Laparoscopy is used for staging in patients with cancer, often before we make a big incision," said Dr. Bouvet.  "Now, we've made it even better with the LED light source.  We modified it so you can see both the normal background of the anatomy plus the fluorescent tumor signal at the same time.  We were able to perform LED fluorescence laparoscopy in mice with small, three millimeter laparoscopes."

The fluorescent marker did not show evidence of toxicity or side effects in the mice.  The combination of LED light and fluorescent markers for malignant tumors could potentially sharpen how surgeons detect and treat pancreatic cancer in human patients.  If patients have received the fluorescent antibodies prior to an operation, the surgeon can insert the LED laparoscope through a small incision and determine if the cancer has metastasized to other areas of the abdomen.  "If it has spread, then we can biopsy those areas and better determine if the best initial treatment should be chemotherapy and save the patient the large incision," Dr. Bouvet said.  "If there's no or limited metastases, then we can more completely remove the primary and metastatic tumors because we can see the edges better.  We're hoping for a lower rate of local recurrence."

Once the cancerous tumors are illuminated, Dr. Bouvet explains, the surgeons are able to more precisely remove the tumor and any surrounding malignant tissue without injuring the aorta and other nearby blood vessels.  Furthermore, another potential application for this technique could involve medically treating pancreatic cancer: "You could tag a specific drug or isotope to target tumor cells.  Since the fluorescent antibodies bind specifically to cancer cells, you could deliver certain payloads of drugs that would kill the cancer cells more effectively," Dr. Bouvet said.

The technique could also be applied to staging and treating colon cancer, which often is expressed through the same antibodies as pancreatic cancer and treated with the same laparoscopic technology.  Within the next four years, Dr. Bouvet plans to work with OncoFluor, Inc., a biotech company that develops fluorescent compounds for malignant tumors, on securing FDA approval for clinical trials of the fluorescent antibodies in humans.

Other members of the research team included Cristina Angela Metildi Raimo, MD; Sharmeela Kaushal, Ph.D.; Chanae Hardamon, BSc, Hop Tran Cao, MD; Cynthia S. Snyder, MD; George A. Luiken, MD; and Mark A. Talamini, MD, FACS, all from the University of California-San Diego, San Diego, CA;  OncoFluor, Inc., San Diego, CA; and AntiCancer, Inc., San Diego, CA.

NOTE: The UCSD research team worked with AntiCancer, Inc. on the mouse model and with laparoscope technicians at Stryker Corporation.  The research is funded by a five-year grant to UCSD and AntiCancer, Inc. from the National Cancer Institute.


'/>"/>
SOURCE American College of Surgeons
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Surgeons Find That Laparoscopic Banding Procedure Helps Overweight Adolescents Lose Weight and Improve Health
2. Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego
3. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
4. PolyTouch Medical Ltd. Receives FDA Clearance to Commercialize PatchAssist(TM) - an Innovative Surgical Instrument Intended to Facilitate the Delivery of Soft Tissue Prosthetics During the Laparoscopic Repair of Soft Tissue Defects
5. Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments
6. Simbionix and USF Receive Grant to Support Development of Laparoscopic Hysterectomy Simulation
7. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
8. Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardicas Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
9. New Micro Laparoscopic Instruments for the Bariatric Surgery Allow for Less Scarring and Pain than Ever Before Possible
10. Ethicon Endo-Surgery Introduces First Powered Endocutter with Enhanced System-Wide Compression and Stability, Allowing Surgeons Greater Control in Laparoscopic Surgery
11. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology:
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home care ... Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its blog ... and read organized content on topics such as home care (generally) as well as ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to create ... by the continuing support of the Jane and Leonard Korman Family Foundation. The ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American ... 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious list ... Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney General ...
(Date:4/27/2017)... ... , ... Offering the purest product of its kind, Swissx Labs AG has ... than the market has seen before. Swissx uses proprietary strains of hemp plants grown ... process for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. ...
Breaking Medicine News(10 mins):